NCT01170897View on ClinicalTrials.gov

Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

October 31, 2013

Study Completion Date

January 31, 2014

Conditions
Solid Tumor
Interventions
DRUG

PEGPH20

PEGylated Recombinant Human Hyaluronidase

Trial Locations (5)

37203

Jeffrey R. Infante, Nashville

48201

Karmanos Cancer Institute, Detroit

85258

Ramesh K. Ramanathan M.D., Scottsdale

85259

Mayo Clinic - Scottsdale, Scottsdale

92024

cCare - California Cancer Associatesfor Research Excellence, Encinitas

Sponsors
All Listed Sponsors
lead

Halozyme Therapeutics

INDUSTRY

NCT01170897 - Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter